Ratings Genmab A/S

Equities

GMAB

DK0010272202

Real-time Estimate Cboe Europe Other stock markets 11:00:00 2024-05-08 am EDT			5-day change	1st Jan Change
2,003 ^DKK	-0.45%		+2.47%	-6.54%

May. 03	GENMAB : A good start to 2024; guidance unchanged
May. 03	Genmab Posts Q1 Net Profit Surge; Revenue Jumps	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company benefits from high valuations in earnings multiples.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last few months, analysts have been revising downwards their earnings forecast.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
GENMAB A/S	-6.45%	18.77B		A-
REGENERON PHARMACEUTICALS, INC.	+10.44%	107B		B+
VERTEX PHARMACEUTICALS INCORPORATED	+0.82%	106B		B+
ARGENX SE	+7.80%	23.47B		B
BIONTECH SE	-13.89%	21.9B		B+
WUXI APPTEC CO., LTD.	-37.26%	17.85B		A-
BEIGENE, LTD.	-10.98%	16.78B		B
NEUROCRINE BIOSCIENCES, INC.	+8.67%	14.41B		C+
SAREPTA THERAPEUTICS, INC.	+41.08%	12.86B		C+
VIKING THERAPEUTICS, INC.	+327.78%	8.78B	-	D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes